Sign inJoin waitlistJoin the waitlist

CD

Chau Dang

Attending Physician · New York Presbyterian Hospital

Credentials: · ·

History

New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1995–1998
Internal Medicine
Allegheny General Hospital
1992–1995
Med Univ of South Carolina Coll of Med
1988–1992

Research

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Cancer Cell · 2018 · 814 citations
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 759 citations
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 711 citations

CH
Clifford Hudis
51 papers
LN
Larry Norton
31 papers
AY
Anthony Yu
28 papers
Richard Steingart
27 papers
Hope Rugo
22 papers
Eric Winer
20 papers
Harold Burstein
20 papers
SM
Shanu Modi
19 papers
Ann Partridge
18 papers
JL
Jennifer Liu
17 papers
Bryan Schneider
16 papers
IK
Ian Krop
16 papers

Clinical trials

Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2017–2026
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2015–2025
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2013–2019
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2011–2019